SCHEMBL5469347

SCHEMBL5469347

O=c1[nH]c2ccccc2cc1-c1csc(-c2ccc(-c3cccs3)s2)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 16/20 0.65
CDK5R1 Q15078 16/20 0.65
KDM4E B2RXH2 2/20 0.50
MEN1 O00255 2/20 0.50
MAPT P10636 2/20 0.50
KMT2A Q03164 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
POLB P06746 1/20 0.50
RAB9A P51151 2/20 0.44
HPGD P15428 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
GLA P06280 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5466202 0.92 CDK5 (0.72) CDK5CDK5R1KDM4EMEN1MAPT
SCHEMBL5464992 0.79 CDK5 (1.00) CDK5CDK5R1MEN1MAPTKMT2A
SCHEMBL5463666 0.78 CDK5 (1.00) CDK5CDK5R1MEN1KMT2A
SCHEMBL31060607 0.78 CDK5 (1.00) CDK5CDK5R1MEN1KMT2A
SCHEMBL4429818 0.78 KDR (0.58) CDK5CDK5R1KDM4ERAB9ANPC1
SCHEMBL5466138 0.77 CDK5 (1.00) CDK5CDK5R1CHEK1KDR
SCHEMBL5467770 0.76 CDK5 (0.73) CDK5CDK5R1KDM4EMAPTKMT2A
SCHEMBL5458361 0.75 CDK5 (0.71) CDK5CDK5R1CHEK1KDR
SCHEMBL5458364 0.75 CDK5 (0.83) CDK5CDK5R1KDM4EKMT2A
SCHEMBL5469022 0.74 CDK5 (0.81) CDK5CDK5R1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032518-A1 Compounds and methods of use AMGEN INC. (US) 2007-02-08 US disclosed
US-20070032518-A1 Compounds and methods of use AMGEN INC. (US) 2007-02-08 US disclosed
US-20070032518-A1 Compounds and methods of use AMGEN INC. (US) 2007-02-08 US disclosed
EP-1478645-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS Amgen Inc. (US) 2004-11-24 EP disclosed
US-6822097-B1 THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS AMGEN, INC. 2004-11-23 US disclosed
WO-2003066630-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS AMGEN INC. (US) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032518-A1 Compounds and methods of use BAX, BAD, CASP3 CDK5 27/4885CDK5R1 147/4885KDM4E 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.